| scholarly article | Q13442814 |
| P2093 | author name string | Timothy P Cripe | |
| Chun-Yu Chen | |||
| Mary Frances Wedekind | |||
| Nicholas L Denton | |||
| P2860 | cites work | Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia | Q24594920 |
| Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma | Q24602657 | ||
| Mutational heterogeneity in cancer and the search for new cancer-associated genes | Q24606956 | ||
| Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program | Q24627862 | ||
| Cancer regression in patients after transfer of genetically engineered lymphocytes | Q24654976 | ||
| The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas | Q24675936 | ||
| Immunotherapy of Childhood Sarcomas | Q26795369 | ||
| Overcoming T cell exhaustion in infection and cancer | Q26829885 | ||
| Immune Checkpoint Blockade in Cancer Therapy | Q26830509 | ||
| Functional Relationship between Tumor-Associated Macrophages and Macrophage Colony-Stimulating Factor as Contributors to Cancer Progression | Q26863784 | ||
| Nivolumab plus ipilimumab in advanced melanoma | Q27852310 | ||
| Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion | Q27860475 | ||
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy | Q28066199 | ||
| Clinical significance of tumor-infiltrating lymphocytes in breast cancer | Q28070214 | ||
| Immune checkpoint blockade: a common denominator approach to cancer therapy | Q28083981 | ||
| Immunotherapy for Bone and Soft Tissue Sarcomas | Q28088363 | ||
| Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade | Q28119095 | ||
| Ipilimumab plus dacarbazine for previously untreated metastatic melanoma | Q28131634 | ||
| Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma | Q36356089 | ||
| Neuroblastomas vary widely in their sensitivities to herpes simplex virotherapy unrelated to virus receptors and susceptibility | Q36547314 | ||
| Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia | Q36619703 | ||
| Silencing of B7-H3 increases gemcitabine sensitivity by promoting apoptosis in pancreatic carcinoma | Q36621122 | ||
| The anticancer immune response: indispensable for therapeutic success? | Q36677608 | ||
| Immunotherapy in pediatric malignancies: current status and future perspectives | Q36691818 | ||
| PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis | Q36750008 | ||
| Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma | Q36822162 | ||
| Feasibility of Pegylated Interferon in Children and Young Adults With Resected High-Risk Melanoma. | Q36927476 | ||
| Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study | Q36999978 | ||
| Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a "common language" for the new arena of cancer treatment | Q37024590 | ||
| Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies | Q37058110 | ||
| Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma | Q37125088 | ||
| A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer | Q37141237 | ||
| Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy | Q37256974 | ||
| T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. | Q37262424 | ||
| Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors | Q37265479 | ||
| Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group | Q37439345 | ||
| Unleashing the therapeutic potential of NOD-like receptors | Q37502679 | ||
| Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy | Q37575208 | ||
| REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer | Q37602536 | ||
| Mifamurtide: a review of its use in the treatment of osteosarcoma | Q37756110 | ||
| The CD4-like molecule LAG-3, biology and therapeutic applications | Q37818246 | ||
| Mifamurtide for the treatment of nonmetastatic osteosarcoma | Q37827876 | ||
| Immune parameters affecting the efficacy of chemotherapeutic regimens | Q37848665 | ||
| Tumor-infiltrating lymphocytes and their significance in melanoma prognosis | Q38164610 | ||
| Regulatory T cells in cancer immunotherapy | Q38177627 | ||
| Sarcoma immunotherapy: past approaches and future directions | Q38207986 | ||
| Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia. | Q38256888 | ||
| Translational biology of osteosarcoma | Q38260633 | ||
| CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic | Q38340574 | ||
| PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy | Q38361400 | ||
| Checkpoint blockade in combination with cancer vaccines | Q38611369 | ||
| Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies | Q38670099 | ||
| Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients | Q38684847 | ||
| Predictive biomarkers for checkpoint inhibitor-based immunotherapy | Q38786289 | ||
| Targeting the PD-1 pathway in pediatric solid tumors and brain tumors | Q38819982 | ||
| Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection? | Q38845362 | ||
| Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges | Q38878906 | ||
| Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions. | Q38902256 | ||
| Progress and opportunities for immune therapeutics in osteosarcoma | Q38948905 | ||
| Drugs in early clinical development for the treatment of osteosarcoma | Q38955517 | ||
| Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer | Q38975751 | ||
| Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ. | Q39017038 | ||
| Treatment-related Death in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. | Q39022649 | ||
| Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. | Q39096595 | ||
| Double‐deleted vaccinia virus in virotherapy for refractory and metastatic pediatric solid tumors | Q39132287 | ||
| Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model | Q39155565 | ||
| Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers | Q39213960 | ||
| Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy | Q39387174 | ||
| Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukemia. | Q39408728 | ||
| Biomarkers of response to PD-1/PD-L1 inhibition. | Q39426306 | ||
| Modulation of the Intratumoral Immune Landscape by Oncolytic Herpes Simplex Virus Virotherapy | Q39427382 | ||
| Combination of lentivector immunization and low‐dose chemotherapy or PD‐1/PD‐L1 blocking primes self‐reactive T cells and induces anti‐tumor immunity | Q39549328 | ||
| Systemic administration of reovirus (Reolysin) inhibits growth of human sarcoma xenografts | Q39562583 | ||
| Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents | Q39581986 | ||
| Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial | Q39704999 | ||
| Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients | Q39714477 | ||
| Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1): Analysis in 5536 Cases Revealed Consistent Expression in Trophoblastic Tumors | Q39783701 | ||
| T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial | Q40186710 | ||
| Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study | Q40295439 | ||
| Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia | Q40312849 | ||
| The B7 and CD28 receptor families | Q40392461 | ||
| A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer | Q40405703 | ||
| CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction | Q40418115 | ||
| Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. | Q40479866 | ||
| Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas | Q40648999 | ||
| Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia | Q40705613 | ||
| Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma | Q41311511 | ||
| Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma | Q41316816 | ||
| Low Frequency of Programmed Death Ligand 1 Expression in Pediatric Cancers | Q41531023 | ||
| Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. | Q41735884 | ||
| Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. | Q41974388 | ||
| Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy | Q41983246 | ||
| Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer | Q42032055 | ||
| TGF-β Inhibition Improves Oncolytic Herpes Viroimmunotherapy in Murine Models of Rhabdomyosarcoma | Q42373489 | ||
| Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent. | Q42378536 | ||
| T-cell immunotherapy: looking forward | Q42549120 | ||
| A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer | Q42940016 | ||
| Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α. | Q43100151 | ||
| A phase II trial of human recombinant interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A Childrens Cancer Group study | Q46141389 | ||
| Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues | Q46308773 | ||
| Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia | Q46385489 | ||
| Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial | Q46559484 | ||
| Natural killer cells can exert a graft-vs-tumor effect in haploidentical stem cell transplantation for pediatric solid tumors. | Q47409937 | ||
| Severe cerebral edema following nivolumab treatment for pediatric glioblastoma: case report. | Q48425815 | ||
| Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications | Q50417083 | ||
| KIR-HLA receptor-ligand mismatch associated with a graft-versus-tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors. | Q51823230 | ||
| Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism. | Q53396593 | ||
| Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression. | Q54396439 | ||
| CD8⁺ tumor-infiltrating lymphocytes at primary sites as a possible prognostic factor of cutaneous angiosarcoma. | Q54586145 | ||
| Immune Checkpoint Inhibitors for Urologic Cancer: The Tip of the Iceberg? | Q56895892 | ||
| Genetic basis for clinical response to CTLA-4 blockade | Q56896243 | ||
| Long-Term Survival for Patients With Non–Small-Cell Lung Cancer With Intratumoral Lymphoid Structures | Q56965922 | ||
| Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival | Q56986695 | ||
| II. Contribution to the Knowledge of Sarcoma | Q58766392 | ||
| A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone | Q68815180 | ||
| Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma | Q70358837 | ||
| Immunologic effects of intermediate-dose IL-2 i.v. after autologous hematopoietic cell transplantation in pediatric solid tumors | Q73656453 | ||
| Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma | Q80789780 | ||
| Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series | Q81104210 | ||
| Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers | Q28256331 | ||
| PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | Q28262647 | ||
| The role of the CD28 receptor during T cell responses to antigen | Q28263234 | ||
| Enhancement of antitumor immunity by CTLA-4 blockade | Q28275730 | ||
| Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports | Q28553328 | ||
| Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | Q29615443 | ||
| Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer | Q29615679 | ||
| Chimeric antigen receptor T cells for sustained remissions in leukemia | Q29617588 | ||
| Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients | Q29617771 | ||
| Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer | Q29619483 | ||
| Chimeric antigen receptor-modified T cells for acute lymphoid leukemia | Q29620130 | ||
| Genetic basis for clinical response to CTLA-4 blockade in melanoma | Q29620594 | ||
| Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2 | Q29620608 | ||
| Nivolumab and ipilimumab versus ipilimumab in untreated melanoma | Q29620657 | ||
| PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma | Q29620878 | ||
| Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer | Q29620902 | ||
| Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer | Q29620913 | ||
| Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias | Q29622949 | ||
| Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good R | Q30357731 | ||
| Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies | Q30827633 | ||
| Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group | Q33398810 | ||
| Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia | Q33437770 | ||
| Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity. | Q33667690 | ||
| NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia | Q33710760 | ||
| Cooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma Models | Q33725706 | ||
| Immunotherapy of childhood cancer: from biologic understanding to clinical application. | Q33752982 | ||
| Ipilimumab and Its Toxicities: A Multidisciplinary Approach | Q33777476 | ||
| CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines | Q33838538 | ||
| „Natural” killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell | Q33906475 | ||
| Review of mifamurtide in the treatment of patients with osteosarcoma | Q33947618 | ||
| Tumor-associated macrophages and survival in classic Hodgkin's lymphoma | Q33962334 | ||
| Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study | Q34042800 | ||
| Identification of a putative regulator of early T cell activation genes | Q34171263 | ||
| Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. | Q34269503 | ||
| T cell major histocompatibility complex class II molecules down-regulate CD4+ T cell clone responses following LAG-3 binding | Q34382009 | ||
| Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance | Q34472025 | ||
| Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma | Q34478015 | ||
| Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study | Q34488726 | ||
| Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy | Q34522172 | ||
| Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases | Q34588395 | ||
| Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study | Q34614776 | ||
| PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors | Q34644359 | ||
| Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. | Q34657638 | ||
| Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study | Q34707770 | ||
| Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis | Q34720087 | ||
| The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection | Q34734469 | ||
| Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group | Q34743615 | ||
| Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma. | Q34996698 | ||
| The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research | Q35000726 | ||
| The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. | Q35009076 | ||
| Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas | Q35070603 | ||
| MHC class I antigens, immune surveillance, and tumor immune escape. | Q35110945 | ||
| Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients | Q35153121 | ||
| A review of the influence of bacterial infection and of bacterial products (Coley's toxins) on malignant tumors in man; a critical analysis of 30 inoperable cases treated by Coley's mixed toxins, in which diagnosis was confirmed by microscopic exam | Q35222693 | ||
| Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors | Q35412152 | ||
| Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma | Q35598804 | ||
| Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma | Q35604043 | ||
| Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma | Q35624496 | ||
| IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas. | Q35690979 | ||
| Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: A report from the Children's Oncology Group | Q35880614 | ||
| Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein. | Q35904943 | ||
| Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments | Q35945493 | ||
| Increased CTLA-4(+) T cells and an increased ratio of monocytes with loss of class II (CD14(+) HLA-DR(lo/neg)) found in aggressive pediatric sarcoma patients | Q35965142 | ||
| Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC). | Q36060283 | ||
| Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. | Q36072022 | ||
| Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group | Q36097717 | ||
| Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma | Q36132720 | ||
| Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer | Q36134480 | ||
| Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy | Q36261159 | ||
| CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. | Q36284594 | ||
| Recognition of Glioma Stem Cells by Genetically Modified T Cells Targeting EGFRvIII and Development of Adoptive Cell Therapy for Glioma | Q36321176 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P433 | issue | 5 | |
| P921 | main subject | immunotherapy | Q1427096 |
| precursor B-cell lymphoblastic leukemia | Q5973974 | ||
| P304 | page(s) | 395-408 | |
| P577 | publication date | 2018-10-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Pediatric Drugs | Q15767256 |
| P1476 | title | Pediatric Cancer Immunotherapy: Opportunities and Challenges | |
| P478 | volume | 20 |
| Q91650568 | Biological treatment of pediatric sarcomas by combined virotherapy and NK cell therapy |
| Q92548970 | Biomarker recommendation for PD-1/PD-L1 immunotherapy development in pediatric cancer based on digital image analysis of PD-L1 and immune cells |
| Q90316280 | Challenges and Opportunities for Childhood Cancer Drug Development |
| Q91763766 | Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition |
| Q92542126 | Current and Future Treatment Strategies for Rhabdomyosarcoma |
| Q89497272 | Drug Resistance Biomarkers and Their Clinical Applications in Childhood Acute Lymphoblastic Leukemia |
| Q91644156 | Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma |
| Q101237465 | Hypoxia and its therapeutic possibilities in paediatric cancers |
| Q92433126 | Immune checkpoint inhibitor therapy for pediatric cancers: A mini review of endocrine adverse events |
| Q91522452 | Immune checkpoint inhibitors for refractory childhood cancers |
| Q91904998 | Immunotherapies for pediatric cancer: current landscape and future perspectives |
| Q92051372 | Immunotherapy in Pediatric Solid Tumors-A Systematic Review |
| Q91842359 | Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours |
Search more.